American Journal of Cardiology
Volume 105, Issue 5 , Pages 656-663, 1 March 2010

Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study)

  • Franklin Zieve, MD, PhD

      Affiliations

    • McGuire Veterans Affairs Medical Center, Richmond, Virginia
    • Corresponding Author InformationCorresponding author: Tel: (804) 675-5151; fax: (804) 675-5139
    • ,
  • Nanette K. Wenger, MD

      Affiliations

    • Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Ori Ben-Yehuda, MD

      Affiliations

    • University of California San Diego Medical Center, San Diego, California
    • ,
  • Christian Constance, MD

      Affiliations

    • Hopital Maisonneuve-Rosemont Recherche Clinique/Polyclinique, Montreal, Quebec, Canada
    • ,
  • Steven Bird, MS

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Raymond Lee, BS

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Mary E. Hanson, PhD

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Charlotte Jones-Burton, MD, MS

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Andrew M. Tershakovec, MD, MPH

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania

Received 3 August 2009; received in revised form 18 October 2009; accepted 18 October 2009. published online 25 December 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Dr. Zieve has received research grants from Amylin Pharmaceuticals, Inc., San Diego, California, Abbott Laboratories, Abbot Park, Illinois, GlaxoSmithKline, London, England, Roche, Basel, Switzerland, Novo-Nordisk, Bagsvaerd, Denmark, Merck & Company, Inc., North Wales, Pennsylvania, and Novartis, Basel, Switzerland; has served on the Speaker's Bureau for Merck & Company, Inc., Abbott Laboratories, and GlaxoSmithKline; and holds stock in Johnson & Johnson, Langhorne, Pennsylvania. Dr. Wenger has received research grants or contracts or has been on the trial steering committee or trial adjudication committee for Pfizer, New York, New York, Merck & Company, Inc., North Wales, Pennsylvania, National Heart, Lung, and Blood Institute, Bethesda, Maryland, CV Therapeutics, Palo Alto, California, Abbott Laboratories, Abbott Park, Illinois, Sanofi-Aventis, Bridgewater, New Jersey, Eli Lilly, Indianapolis, Indiana and has acted as a consultant or advisor for Schering-Plough, Kenilworth, New Jersey; AstraZeneca, Wilmington, Delaware; Abbott Laboratories, Abbott Park, Illinois; Merck & Company, Inc., North Wales, Pennsylvania; Pfizer, New York, New York; Boston Scientific, Boston, Massachusetts; and Medtronic, Minneapolis, Minnesota. Dr. Constance has served on the Speaker's Bureau for Merck & Company, Inc., North Wales, Pennsylvania. Dr. Ben-Yehuda has received research grants from Merck & Company, Inc., North Wales, Pennsylvania, and Merck/Schering-Plough, North Wales, Pennsylvania, has served on the Speaker's Bureau for Schering-Plough, Kenilworth, New Jersey, and has acted as a consultant for CV Therapeutics, Palo Alto, California, and Merck & Company, Inc., Drs. Bird, Lee, Hanson, Jones-Burton, and Tershakovec are employees of Merck & Company, Inc., North Wales, Pennsylvania, and might own stock and/or hold stock options in the company.

 All authors were involved in at least one of the following: conception, design, acquisition, analysis, statistical analysis, interpretation of data, drafting the manuscript, and/or revising the manuscript for important intellectual content. All authors provided final approval of the version to be published.

PII: S0002-9149(09)02552-1

doi:10.1016/j.amjcard.2009.10.029

American Journal of Cardiology
Volume 105, Issue 5 , Pages 656-663, 1 March 2010

Article Tools

* Image Usage & Resolution